Overview

Low-Dose Enoxaparin in Psoriasis

Status:
NOT_YET_RECRUITING
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Rationale: * Psoriasis is a chronic immune-mediated inflammatory skin disorder where T cells play a fundamental role in its pathogenesis. * Low molecular weight heparin has been reported to exert immunomodulatory effect at small doses through inhibition of T cells heparinase enzyme. * Low molecular weight heparin may have promising results for treatment of psoriasis. Research question: * Can low molecular weight heparin be used safely for treatment of psoriasis with good outcome? * Is enoxaparin inhibitory effect on T cell heparinase enzyme responsible for its beneficial effect? Hypothesis: * Low molecular weight heparin can achieve good results when used at small doses for treatment of psoriasis. * Heparin can exert immunomodulatory effect in psoriasis through inhibition of T cell heparinase enzyme. AIM OF WORK -The aim of this work is to assess the possible clinical efficacy and safety of low-dose enoxaparin in the treatment of psoriasis and to detect if inhibition of heparinase enzyme might account for its beneficial therapeutic effect. Objectives: * To evaluate safety and efficacy of low molecular weight heparin at small dose for treatment of psoriasis. * Contribute to the ongoing efforts to optimize psoriasis management and improve the lives of individuals affected by this chronic condition.
Phase:
NA
Details
Lead Sponsor:
Zagazig University